Transcatheter aortic valve replacement (TAVR)

Clinical evidence

The Medtronic CoreValve™/Evolut™ platform is supported by a robust body of clinical evidence.

Explore the CoreValve/Evolut clinical success.

Comprehensive clinical evidence

Stay up to date on the latest clinical evidence from Medtronic. Key summaries demonstrate the efficacy of the CoreValve/Evolut TAVR platform.

Real-world results

The CoreValve/Evolut platform provides reproducible results from clinical trial to the real world.  

Explore our STS/ACC TVT Registry™* data that supports the excellent clinical performance seen in our trials.

EXPAND TAVR II Pivotal Trial

The purpose of the EXPAND TAVR II Pivotal Trial is to explore the treatment of moderate aortic stenosis (AS) with early aortic valve replacement (AVR) before AS becomes severe, leading to preservation of cardiac function, prevention of further deterioration in cardiac function, and prevention of death in some patients.

Connect with us on social.

Twitter: @MDT_StructHeart 

LinkedIn: Medtronic Cardiac and Vascular

Get support.

Reach out to LifeLine CardioVascular Tech Support with questions.


Stay informed.

Sign up to get the latest information and resources from Medtronic on treating aortic stenosis and the Evolut platform.


™Third-party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.